January 2026 in “Dermatology Online Journal” Female-marketed minoxidil foam is more expensive than male-marketed, but generic and bulk options can reduce this gap.
36 citations
,
September 2018 in “Dermatologic Therapy” This study found that 78% of patients continued taking oral minoxidil for androgenetic or traction alopecia, with 33% reporting decreased hair shedding and 28% noting increased scalp hair.
January 2026 in “Frontiers in Pharmacology” This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.
In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.
39 citations
,
February 2021 in “Journal of The American Academy of Dermatology” In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.